The impact of COVID-19 on people with cardiovascular disease (CVD) has been significant, with almost 30% of people hospitalised during the pandemic having chronic cardiac disease.  Perhaps more worryingly is that significantly fewer people presented to A&E with suspected MI during this period; the BHF reported data from hospitals across England showing that the number of people seen in hospital with a suspected heart attack halved from March to April during the pandemic.

​

Alongside atrial fibrillation (A) and blood pressure (B), cholesterol (C) is a major risk factor for CVD, yet it is often overlooked in assessment and treatment.   If we are to reduce risk for this vulnerable group of people, and achieve the aim of the LTP to reduce CVD events by 150,000 over the next 10 years, all three ABC risk factors need to be addressed.

 

This free webinar sponsored by Amgen and chaired by Dr Matt Kearney, Director of Primary care Innovation at UCLPartners and former National Clinical Director for CVD Prevention at NHS England , will focus on the opportunities to reduce the risk of people experiencing cardiac events due to raised cholesterol to help achieve the NHS Long-Term Plan ambitions.  Our expert panel including Helen Williams, National specialty adviser for cardiovascular disease prevention, Jules Payne, Chief Executive of Heart UK and Russell Abberley, General Manager, Amgen UK will share best practice, identify what patients want and need from their care and discuss how we can harness some of the innovation generated by COVID-19 to reduce the risk in people living with CVD and raised cholesterol. 

​

This webinar has been jointly organised by Govconnect and Amgen, and funded by Amgen.